md-medicaldata

Authors

 

Miloš Jakovljević ¹, Žaklina Stanković ², Jana Kocić <sup>3

1</sup>Dom zdravlja Kruševac,
²Dom zdravlja Medveđa,
³Medicinski fakultet Univerziteta u Nišu

 

UDK: 616.71-006.44

The paper was received / Rad primljen: 13.01.2022.

Accepted / Rad prihvaćen: 15.02.2022.

 

 

Sažetak

 

 

Na globalnom nivou incidencija multiplog mijeloma je u porastu, tako da je uvođenje jedinstvene strategije dijagnostikovanja i novih terapijskih principa neophodno. Etiologija ove bolesti nije do kraja utvrđena, tako da je lečenje otežano. Dijagnoza multiplog mijeloma se zasniva na: inicijalnoj, prognostički-značajnoj i dopunskoj dijagnostici i teško je sprovodljiva u primarnoj zdravstvenoj zaštiti u kompletnom obimu. Terapijske smernice savremenog lečenja zasnovane su na analizi prognostičkog profila bolesnika, individualnog terapijskog pristupa, proceni stepena i dužine terapijskog odgovora. U skladu sa dobijenim rezultatima osnova lečenja multiplog mijeloma u budućnosti išla bi u pravcu kombinovanja terapije sa bortezomibom  proteazom inhibitorom.

 

Ključne reči:

multipli mijelom, primarna zdravstvena zaštita, savremena terapija

 

 

 

Abstract

The global incidence of multiple myeloma is generally in the rise, so the introduction of a uniform strategy for diagnostics and new therapy principles is necessary. The ethiology of this disease does not have full determination cycles and due to that the treatment of disease is hard. Definitive causes of multiple myeloma are not well known yet. The basic diagnostics covers initial, prognoses-significant and additional diagnostics but they all hard to implement in primary health care in full volume. Modern therapy principles include the analysis of patients prognosis profile, adjusted therapy method, evaluation of the level and length of treatment response. In accordance with acquired results, the foundation of multiple myeloma therapy in the future will probably proceed in a form of combined Bortesomib proteasome inhibitor therapy.

 

Key words:

multiple myeloma, primary health care, modern therapy

 

 

 

 

References:

1. Ferreira CR. The burden of rare diseases. Am J Med Genet A. 2019;179(6):885-892.
2. Padala, S.A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., Ajebo, G.H. Epidemiology, Staging and Management of Multiple Myeloma. Medical sciences (Basel, Switzerland)2021; 9(1): 3.
3. Balkanov, S. K., Trajkova, S., Stavric, S. G., Pivkova, A., Veljanovska, M. P. L., Spasovski, D.et al. Myeloma multiplex treatment and overall survival. Mac. Pharm. Bull. 2021; 67(1)
4. Jakovljević Miloš. Savremena terapija multiplog mijeloma. Diplomski rad. Medicinski fakultet Univerziteta u Nišu, 2011.
5. Tricot G. Multiple Myeloma and Other Plasma Cell Disorders. In Hoffman R. (ed): Hematology-Basic Principles and Practice. New York, 2004: 1501-35.
6. Rajkumar SV. Updated  Diagnostic Criteria and Staging System for Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2016;35:e418-23.
7. Forsberg PA, Hammes A, Abbott D, Sherbenou DW, Rossi A, Jayabalan D, Niesvizky R, Mark TM, Ely S. Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma. Leuk Lymphoma. 2019;60(8):2085-2087.
8. San-Miguel JF, Paiva B, Gutiérrez NC. New tools for diagnosis and monitoring of multiple myeloma. Am Soc Clin Oncol Educ Book. 2013. 
9. Kehrer, M., Koob, S., Strauss, A., Wirtz, D.C., Schmolders, J. Multiples Myelom-aktuelle Standards in Diagnostik und Therapie [Multiple Myeloma - Current Status in Diagnostic Testing and Therapy]. Zeitschrift fur Orthopadie und Unfallchirurgie 2017<155(5), 575-586.
10. Boyle EM, Proszek PZ, Kaiser MF, Begum D, Dahir N, Savola S, Wardell CP, Leleu X, Ross FM, Chiecchio L, Cook G, Drayson MT, Owen RG, Ashcroft JM, Jackson GH, Anthony Child J, Davies FE, Walker BA, Morgan GJ. A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma. Genes Chromosomes Cancer. 2015;54(2):91-8.
11. Bila, J., Katodritou, E., Guenova, M., Basic-Kinda, S., Coriu, D., Dapcevic, M. et al. Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group. Journal of clinical medicine 2021;10(17): 3940.
12. Durie B, Salmon S. A clinical staging system for multiple myeloma. Cancer, 1975; 36: 842-54.
13. Larocca, A., Niesvizky, R., Morgan, G., Landgren, O., Hajek, R., Einsele, H. et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2014,32(6), 587-600.
14. Ely S, Forsberg P, Ouansafi I, Rossi A, Modin A, Pearse R, Pekle K, et al. Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. Clin Lymphoma Myeloma Leuk. 2017;17(12):825-833.
15. Fonseca, R., Abouzaid, S., Bonafede, M., Cai, Q., Parikh, K., Cosler, L., Richardson, P., Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia 2017.31(9), 1915-1921.
16. Govedarović N, Vukičević T. [Current approaches to supportive care in multiple myeloma]. Srp Arh Celok Lek. 2011;139 Suppl 2:123-8.
17. Smith ML, Newland AC. Treatment of myeloma. QJM. 1999 Jan;92(1):11-4. 
18. Palumbo, A., Bringhen, S., Ludwig, H., Dimopoulos, M.A., Bladé, J., Mateos, M.Vet al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011; 118(17), 4519-4529.
19. van de Donk, N., Pawlyn, C., Yong, K.L., Multiple myeloma. Lancet (London, England) 2021; 397(10272): 410-427.
20. Munishi CN. Investigative tools for diagnosis and menagement. Hematology, 2008: 298-305.
21. Durie M.B. et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-73.
22. Svetlana Balkanov K, Sotirova T, Genadieva SS, Cevreska L, Stojanovik A, Balkanov T. Adverse effects of thalidomide administration, in patients with myeloma multiplex? Mater Sociomed. 2014;26(2):134-6. 
23. Palumbo et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood, 2008; 111: 3968-77.
24. Hardi A, Varga G, Nagy Z, Kosztolányi S, Váróczy L, Plander M, Schneider T, Demeter J, Alizadeh H, Illés Á, Masszi T, Mikala G. [Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime].Orv Hetil. 2021;162(36):1451-1458.
25. Ljungman P. et al. Allogeneic and autologous transplantation for hematological diseases, solid tumours and immune disorders: Deffinitions and current practice in Europe. Bone marrow transplant, 2006; 37: 439-49.
26. Ludwig H. & Zojer N. Supportive care in multiple myeloma. Best practice and research Clinical hematology, 2007; 20: 817-35.
27. Smith A. et al. Guidelines on the diagnosis and management of multiple myeloma 2005. Br  J of Hematology, 2005; 132: 410-51.
28. Greipp et al. Development of an International Prognostic Index (IPI) for myeloma: report of the International Myeloma Working Group. Hematol J, 2003; 4: 542-4.
29. Stewart A.K. et al. A practical guide to defining high-risk myeloma for clinical trials, patient conselling, and choice of therapy. Leukemia, 2007; 21: 523-34.
30. San Miguel J. et al. Individualising treatment of patients with myeloma in the era of novel agents. J Clin Oncol, 2008; 26 (16).
31. Anderson C. K. et al. Clinically relevant and points and new drug aprovalls for myeloma. Leukemia, 2008; 22: 231-9.
32. Palumbo, A., Rajkumar, S.V., San Miguel, J.F., Tandon, N., Sidana, S., Rajkumar, S.Vet al. Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. Blood advances2019< 3(5), 744-750.
    

PDF: Jakovljević M. et al MD-Medical Data 2022;14(1-2): 007-012